Eraxis

Eraxis

anidulafungin

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Full Prescribing Info
Contents
Anidulafungin.
Description
Vials containing 100 mg anidulafungin powder for solution for infusion (see Special precautions for disposal and other handling under Cautions for Usage).
The reconstituted solution contains 3.33 mg/mL anidulafungin and the diluted solution contains 0.77 mg/mL anidulafungin.
Excipients/Inactive Ingredients: Powder: Fructose, Mannitol, Ppolysorbate 80, Tartaric acid, Sodium hydroxide (for pH-adjustment), Hydrochloric acid (for pH-adjustment), Nitrogen, Water for injection.
Action
Pharmacotherapeutic Group: Antimycotics for systemic use, other antimycotics. ATC Code: JO2 AX 06.
Pharmacology: Pharmacodynamics: Mode of Action: Anidulafungin is a semi-synthetic echinocandin, a lipopeptide synthesised from a fermentation product of Aspergillus nidulans.
Anidulafungin selectively inhibits 1,3-β-D glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall. Anidulafungin has shown fungicidal activity against Candida species and activity against regions of active cell growth of the hyphae of Aspergillus fumigatus.
Activity in vitro: Anidulafungin is active in vitro against Candida spp. including C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. lusitaniae, C. guilliermondii and Aspergillus species including A. fumigatus, A. flavus, A. niger, and A. terreus. Its activity is not affected by resistance to other classes of antifungal agents.
MICs were determined according to the Clinical and Laboratory Standard Institute (CLSI) approved standard reference methods M27 and M38. The relationship between clinical response and in vitro activity remains to be elucidated.
There have been reports of Candida isolates with reduced susceptibility to echinocandins including anidulafungin, but the clinical significance of this observation is unknown.
Activity in vivo: Parenterally administered anidulafungin was effective against Candida spp. in immunocompetent and immunocompromised mouse and rabbit models. Anidulafungin treatment prolonged survival and also reduced the organ burden of Candida spp.
Experimental infections included disseminated C. albicans infection in neutropenic rabbits, esophageal/oropharyngeal infection of neutropaenic rabbits with fluconazole-resistant C. albicans and disseminated infection of neutropaenic mice with fluconazole-resistant C. glabrata.
Anidulafungin has also demonstrated activity against Aspergillus fumigatus in mouse and rabbit infection models.
In combination with other antifungal agents: In vitro studies of anidulafunginin combination with fluconazole, itraconazole and amphotericin B suggest no antagonism of antifungal activity against Candida species. The clinical significance of these results is unknown. In vitro studies have evaluated the activity of anidulafungin in combination with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. The combination of anidulafungin and amphotericin B showed indifference for 16 of 26 isolates, while anidulafungin in combination with either itraconazole or voriconazole showed synergy against 18 of 26 isolates. The clinical significance of these results is unknown.
Information from Clinical Studies: Candidemia and other forms of invasive candidiasis: The safety and efficacy of anidulafungin were evaluated in a pivotal, Phase 3, randomised, double-blind, multicentre, multinational study of patients with candidemia. Patients were randomised to receive once daily i.v. anidulafungin (200 mg loading dose followed by 100 mg maintenance dose) or i.v. fluconazole (800 mg loading dose followed by 400 mg maintenance dose). Patients were stratified by APACHE II score (≤20 and >20) and the presence or absence of neutropenia. Patients with Candida endocarditis, osteomyelitis or meningitis, or those with infection due to C. krusei, were excluded from the study. Treatment was administered for at least 14 and not more than 42 days. Patients in both study arms were permitted to switch to oral fluconazole after at least 10 days of intravenous therapy, provided that they were able to tolerate oral medication, were afebrile for at least 24 hours, and the most recent blood cultures were negative for Candida species.
Patients who received at least one dose of study medication and who had a positive culture for Candida species from a normally sterile site before entry into the study (modified intent-to-treat [MITT] population) were included in the primary analysis of global response at the end of i.v. therapy. A successful global response required clinical improvement and microbiological eradication. Patients were followed for six weeks beyond the end of all therapy.
Two hundred and fifty-six patients (aged 16 to 91 years) were randomised to treatment and received at least one dose of study medication. Two hundred and forty-five patients (127 anidulafungin, 118 fluconazole) met the criteria for inclusion in the MITT population. Of these, 219 patients (116 anidulafungin (91.3%), 103 fluconazole (87.3%)) had candidemia only; 5.5% patients in the anidulafungin arm and 9.3% patients in the fluconazole arm had infections at other normally sterile sites; finally 3.1% patients in the anidulafungin arm and 3.4% patients in the fluconazole arm had both (candidemia and infections at other normally sterile sites). The most frequent species isolated at baseline were C. albicans (63.8% anidulafungin, 59.3% fluconazole), followed by C. glabrata (15.7%, 25.4%), C. parapsilosis (10.2%, 13.6%) and C. tropicalis (11.8%, 9.3%). The majority (97%) of patients were nonneutropenic (ANC >500) and 81% had APACHE II scores less than or equal to 20.
At the end of i.v. therapy, anidulafungin was superior to fluconazole in the treatment of patients with candidemia and/or other forms of invasive candidiasis. In the anidulafungin arm, 96 patients (75.6%) had global success versus 71 patients (60.2%) in the fluconazole arm. The between group difference in global success rate (anidulafungin global success rate minus fluconazole global success rate) was 15.4% (95% CI: 3.9, 27.0).
Candida infections in neutropenic patients: The efficacy of anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) in adult neutropenic patients (defined as absolute neutrophil count ≤500 cells/mm3, WBC ≤500 cells/mm3 or classified by the investigator as neutropenic at baseline) with microbiologically confirmed invasive candidiasis was assessed in an analysis of pooled data from 5 prospective studies (1 comparative versus caspofungin and 4 open-label, non-comparative). Patients were treated for at least 14 days. In clinically stable patients, a switch to oral azole therapy was permitted after at least 5 to 10 days of treatment with anidulafungin. A total of 46 patients were included in the analysis. The majority of patients had candidemia only (84.8%; 39/46). The most common pathogens isolated at baseline were C. tropicalis (34.8%; 16/46), C. krusei (19.6%; 9/46), C. parapsilosis (17.4%; 8/46), C. albicans (15.2%; 7/46), and C. glabrata (15.2%; 7/46). The successful global response rate at End of Intravenous Treatment (primary endpoint) was 26/46 (56.5%) and End of All Treatment was 24/46 (52.2%). All-cause mortality up to the end of the study (6 Week Follow-up Visit) was 21/46 (45.7%).
The efficacy of anidulafungin in adult neutropenic patients (defined as absolute neutrophil count ≤500 cells/mm3 at baseline) with invasive candidiasis was assessed in a prospective, double-blind, randomized, controlled trial. Eligible patients received either anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) or caspofungin (70 mg intravenous loading dose followed by 50 mg intravenous daily) (2:1 randomization). Patients were treated for at least 14 days. In clinically stable patients, a switch to oral azole therapy was permitted after at least 10 days of study treatment. A total of 14 neutropenic patients with microbiologically confirmed invasive candidiasis (MITT population) were enrolled in the study (11 anidulafungin; 3 caspofungin). The majority of patients had candidemia only. The most common pathogens isolated at baseline were C. tropicalis (4 anidulafungin, 0 caspofungin), C. parapsilosis (2 anidulafungin, 1 caspofungin), C. krusei (2 anidulafungin, 1 caspofungin), and C. ciferrii (2 anidulafungin, 0 caspofungin). The successful global response rate at the End of Intravenous Treatment (primary endpoint) was 8/11 (72.7%) for anidulafungin and 3/3 (100.0%) for caspofungin (difference -27.3, 95% CI -80.9, 40.3); the successful global response rate at the End of All Treatment was 8/11 (72.7%) for anidulafungin and 3/3 (100.0%) for caspofungin (difference -27.3, 95% CI -80.9, 40.3). All-cause mortality up to the 6 Week Follow-Up visit for anidulafungin (MITT population) was 4/11 (36.4%) and 2/3 (66.7%) for caspofungin.
Patients with microbiologically confirmed invasive candidiasis (MITT population) and neutropenia were identified in an analysis of pooled data from 4 similarly designed prospective, open-label, noncomparative studies. The efficacy of anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) was assessed in 35 adult neutropenic patients defined as absolute neutrophil count ≤500 cells/mm3 or WBC ≤500 cells/mm3 in 22 patients or classified by the investigator as neutropenic at baseline in 13 patients. All patients were treated for at least 14 days. In clinically stable patients, a switch to oral azole therapy was permitted after at least 5 to 10 days of treatment with anidulafungin. The majority of patients had candidemia only (85.7%). The most common pathogens isolated at baseline were C. tropicalis (12 patients), C. albicans (7 patients), C. glabrata (7 patients), C. krusei (7 patients), and C. parapsilosis (6 patients). The successful global response rate at the End of Intravenous Treatment (primary endpoint) was 18/35 (51.4%) and 16/35 (45.7%) at the End of All Treatment. All-cause mortality by Day 28 was 10/35 (28.6%). The successful global response rate at End of Intravenous Treatment and End of All Treatment were both 7/13 (53.8%) in the 13 patients with neutropenia assessed by investigators at baseline.
Deep tissue infections: The efficacy of anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) in adult patients with microbiologically confirmed deep tissue candidiasis was assessed in an analysis of pooled data from 5 prospective studies (1 comparative and 4 open-label). Patients were treated for at least 14 days. In the 4 open-label studies, a switch to oral azole therapy was permitted after at least 5 to 10 days of treatment with anidulafungin. A total of 129 patients were included in the analysis. Twenty one (16.3%) had concomitant candidemia. The mean APACHE II score was 14.9 (range, 2 - 44). The most common sites of infection included the peritoneal cavity (54.3%; 70 of 129), hepatobiliary tract (7.0%; 9 of 129), pleural cavity (5.4%; 7 of 129) and kidney (3.1%; 4 of 129). The most common pathogens isolated from a deep tissue site at baseline were C. albicans (64.3%; 83 of 129), C. glabrata (31.0%; 40 of 129), C. tropicalis (11.6%; 15 of 129), and C. krusei (5.4%; 7 of 129). The successful global response rate at the end of intravenous treatment (primary endpoint) and end of all treatment and all-cause mortality up to the 6 week follow-up visit is shown in Table 1. (See Table 1.)

Click on icon to see table/diagram/image

Pharmacokinetics: The pharmacokinetics of anidulafungin have been characterized by a rapid distribution half-life (0.5-1 hour) and a volume of distribution of 30-50 L that is similar to total body fluid volume. Anidulafungin is extensively bound (>99%) to human plasma proteins.
Biotransformation: Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not clinically relevant substrate, inducer, or inhibitor of cytochrome P450 isoenzymes. It is unlikely that anidulafungin will have clinically relevant effects on the metabolism of drugs metabolized by cytochrome P450 isoenzymes.
Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity. The degradation half-life of anidulafungin under physiologic conditions is approximately 24 hours. In vivo, the ring-opened product is subsequently converted to peptidic degradants and eliminated mainly through biliary excretion.
Elimination: The clearance of anidulafungin is about 1 L/h. Anidulafungin has a predominant elimination half-life of approximately 24 hours that characterizes the majority of the plasma concentration-time profile and a terminal half-life of 40-50 hours that characterizes the terminal elimination phase of the profile.
In a single-dose clinical study, radiolabeled (14C) anidulafungin (~88 mg) was administered to healthy subjects. Approximately 30% of the administered radioactive dose was eliminated in the faeces over 9 days, of which less than 10% was intact drug. Less than 1% of the administered radioactive dose was excreted in the urine. Anidulafungin concentrations fell below the lower limits of quantitation 6 days post-dose. Negligible amounts of drug-derived radioactivity were recovered in blood, urine, and faeces 8 weeks post-dose.
Linearity: Anidulafungin displays linear pharmacokinetics across a wide range of once daily doses (15-130 mg).
Special Populations: Patients with fungal infections: The pharmacokinetics of anidulafungin in patients with fungal infections are similar to those observed in healthy subjects based on population pharmacokinetic analyses. With the 200/100 mg daily dose regimen at an infusion rate of 1 mg/min, the steady state Cmax and trough concentrations Cmin could reach approximately 7 and 3 mg/L, respectively, with an average steady state AUC of approximately 110 mg·h/L.
Weight: Though weight was identified as a source of variability in clearance in the population pharmacokinetic analysis, weight has little clinical relevance on the pharmacokinetics of anidulafungin.
Gender: Plasma concentrations of anidulafungin in healthy men and women were similar. In multiple-dose patient studies, drug clearance was slightly faster (approximately 22%) in men.
Elderly: The population pharmacokinetic analysis showed that median clearance differed slightly between the elderly group (patients ≥65, median CL = 1.07 L/h) and the non-elderly group (patients <65, median CL = 1.22 L/h), however, the range of clearance was similar.
Ethnicity: Anidulafungin pharmacokinetics were similar among Caucasian, Blacks, Asians, and Hispanics.
HIV Positivity: Dosage adjustments are not required based on HIV positivity, irrespective of concomitant anti-retroviral therapy.
Hepatic Insufficiency: Anidulafungin is not hepatically metabolised. Anidulafungin pharmacokinetics were examined in subjects with Child-Pugh class A, B or C hepatic insufficiency. Anidulafungin concentrations were not increased in subjects with any degree of hepatic insufficiency. Although a slight decrease in AUC was observed in patients with Child-Pugh C hepatic insufficiency, the decrease was within the range of population estimates noted for healthy subjects.
Renal Insufficiency: Anidulafungin has negligible renal clearance (<1%). In a clinical study of subjects with mild, moderate, severe or end stage (dialysis-dependent) renal insufficiency, anidulafungin pharmacokinetics were similar to those observed in subjects with normal renal function. Anidulafungin is not dialyzable and may be administered without regard to the timing of hemodialysis.
Pediatric: The pharmacokinetics of anidulafungin after daily doses were investigated in 24 immunocompromised paediatric (2 to 11 years old) and adolescent (12 to 17 years old) patients with neutropenia. The steady state was achieved on the first day after a loading dose (twice the maintenance dose), and the steady state Cmax and AUCss increase in a dose-proportional manner. The systemic exposures following the daily maintenance doses, 0.75 and 1.5 mg/kg/day in patients aged 2 to 17 years old were comparable to those observed in adults following 50 and 100 mg/day, respectively.
Toxicology: Preclinical safety data: Non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, acute toxicity, repeated dose toxicity, and toxicity to reproduction. In 3 months studies, evidence of liver toxicity, including elevated enzymes and morphologic alterations, was observed in both rats and monkeys at doses 4 to 6-fold higher than the anticipated clinical therapeutic exposure. In vitro and in vivo genotoxicity studies with anidulafungin provided no evidence of genotoxic potential. Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of anidulafungin.
Administration of anidulafungin to rats did not indicate any effects on reproduction, including male and female fertility.
Anidulafungin crossed the placental barrier in rats and was detected in fetal plasma. The potential risk to the human fetus is unknown.
Anidulafungin was found in the milk of lactating rats. It is not known whether anidulafungin is excreted in human milk.
Anidulafungin did not produce any drug-related development toxicity in rats at the highest dose of 20 mg/kg/day, a dose equivalent to 2 times the proposed therapeutic maintenance dose of 100 mg on the basis of relative body surface area. Developmental effects observed in rabbits (slightly reduced fetal weights) occurred in the high dose group, a dose that also produced maternal toxicity.
Indications/Uses
Treatment of invasive candidiasis, including candidemia, in adult patients (see Pharmacology: Pharmacodynamics under Actions and Precautions).
Dosage/Direction for Use
Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.
A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter. Duration of treatment should be based on the patient's clinical response. In general, antifungal therapy should continue for at least 14 days after the last positive culture.
Anidulafungin should be reconstituted with water for injection to a concentration of 3.33 mg/mL and subsequently diluted to a concentration of 0.77 mg/mL before use according to the instructions given in Special precautions for disposal and other handling under Cautions for Usage.
It is recommended that anidulafungin is administered at a maximum rate of infusion that does not exceed 1.1 mg/minute (see Precautions, Adverse Reactions and Special precautions for disposal and other handling under Cautions for Usage).
Renal and hepatic impairment: No dosing adjustments are required for patients with mild, moderate, or severe hepatic impairment. No dosing adjustments are required for patients with any degree of renal insufficiency, including those on dialysis. Anidulafungin can be given without regard to the timing of haemodialysis (see Pharmacology: Pharmacokinetics under Actions).
Other special populations: No dosing adjustments are required for adult patients based on patient gender, weight, ethnicity, HIV positivitity, or geriatric status.
Children and adolescents: The experience in children is limited (see Pharmacology: Pharmacokinetics under Actions). Use in patients under 18 years of age is not recommended until further data becomes available, unless the potential benefit justifies the risk.
Overdosage
As with any overdose, general supportive measures should be utilized as necessary.
During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. In a study of 10 healthy subjects administered a loading dose of 260 mg followed by 130 mg daily, anidulafungin was well tolerated with no dose limiting toxicity; 3 of the 10 subjects experienced transient, asymptomatic transaminase elevations (≤3 x ULN).
Anidulafungin is not dialysable.
Contraindications
Hypersensitivity to the active substance, or to any of the excipients.
Hypersensitivity to other medicinal products of the echinocandin class (e.g. caspofungin).
Special Precautions
Anidulafungin has not been studied in patients with Candida endocarditis, osteomyelitis or meningitis.The efficacy of anidulafungin has only been evaluated in a limited number of neutropenic patients (see Pharmacology: Pharmacodynamics under Actions).
Anaphylactic Reactions:
Anaphylactic reactions, including shock, were reported with the use of anidulafungin. If these reactions occur, anidulafungin should be discontinued and appropriate treatment administered. (See Adverse Reactions).
Infusion-Related Reactions: Infusion-related adverse events have been reported with anidulafungin, including rash, urticaria, flushing, pruritus, dyspnea, bronchospasm and hypotension. Infusion-related adverse events are infrequent when the rate of anidulafungin infusion does not exceed 1.1 mg/minute (see Dosage & Administration, Adverse Reactions and Cautions for Usage).
Hepatic Effects: Laboratory abnormalities in liver function tests have been seen in healthy subjects and patients treated with anidulafungin. In some patients with serious underlying medical conditions who were receiving multiple concomitant medications along with anidulafungin, clinically significant hepatic abnormalities have occurred. Isolated cases of significant hepatic dysfunction, hepatitis, or hepatic failure have been reported in patients; a causal relationship to anidulafungin has not been established. Patients who develop abnormal liver function tests during anidulafungin therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing anidulafungin therapy.
Effects on ability to drive and use machines: No studies on the effects on the ability to drive and use machines have been performed.
Use In Pregnancy & Lactation
Animal studies have shown no selective reproductive toxicity (see Pharmacology: Toxicology: Preclinical Safety Data under Actions). There are no adequate or well-controlled data regarding the use of anidulafungin in pregnant women. Therefore, anidulafungin should only be used during pregnancy if the potential benefit to the mother outweighs the potential risk to the fetus.
Animal studies have shown excretion of anidulafungin in breast milk. It is not known whether anidulafungin is excreted in human breast milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with anidulafungin should be made taking into account the benefit of breast-feeding to the child and the benefit of anidulafungin to the mother.
Adverse Reactions
Fifteen hundred and sixty-five (1565) patients received intravenous anidulafungin in clinical trials (1308 in Phase 2/3 studies and 257 in Phase I studies).
The safety profile of anidulafungin is based on 840 patients with candidaemia/invasive candidiasis receiving the recommended daily dose of 100 mg in 9 studies. Three studies (one comparative vs. fluconazole, 2 non-comparative) assessed the efficacy of anidulafungin (100 mg) in patients with candidaemia and other deep tissue Candida infections. In these three studies [invasive candidiasis/candidaemia (ICC) database], a total of 204 patients received anidulafungin, 119 for ≥14 days. In six additional studies (two comparative vs. caspofungin and four non-comparative), 636 patients including 53 neutropenic patients and 131 patients with deep tissue infection were studied; the mean durations of intravenous treatment in neutropenic patients and patients with deep tissue infection in these studies were 10.0 (range, 1 to 42 days) and 14.0 (range, 1 to 42 days) days, respectively. Adverse events were typically mild to moderate and seldom led to discontinuation.
The following table includes the all-causality adverse events (MedDRA terms) from 840 subjects receiving 100 mg anidulafungin.
Infusion-related adverse events have been reported with anidulafungin, including rash, urticaria, flushing, pruritus, dyspnea, bronchospasm and hypotension (see Precautions). (See Table 2.)

Click on icon to see table/diagram/image

In the safety assessment of the Phase 2/3 patient population (N = 669), the following additional adverse events were of note: neutropenia, leukopenia, anaemia, hyperuricaemia, hypocalcaemia, hyponatraemia, hypoalbuminaemia, hypophosphataemia, anxiety, delirium, confusional state, hallucination auditory, dizziness, paraesthesia, central pontine myelinolysis, dysgeusia, Guillain-Barre syndrome, tremor, altered visual depth perception, deafness unilateral, phlebitis, thrombophlebitis superficial, hypotension, lymphangitis, dyspepsia, dry mouth, oesophageal ulcer, hepatic necrosis, angioneurotic edema, hyperhidrosis, myalgia, monoarthritis, renal failure, haematuria, pyrexia, chills, oedema peripheral, injection site reaction, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, lymphocyte count decreased.

Drug Interactions
Preclinical in vitro and in vivo studies and clinical studies have demonstrated that anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 isoenzymes. Interaction studies have only been performed in adults. Anidulafungin has negligible renal clearance (<1%). Minimal interactions are expected with the concomitant medications (see Pharmacology: Pharmacokinetics under Actions).
In vitro studies showed that anidulafungin is not metabolized by human cytochrome P450 or by isolated human hepatocytes, and anidulafungin does not significantly inhibit the activities of human CYP isoforms (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A) at clinically relevant concentrations.
No clinically relevant drug-drug interactions were observed with the following drugs likely to be co-administered with anidulafungin.
Cyclosporin (CYP3A4 substrate): In a study of 12 healthy adult subjects who received 100 mg/day anidulafungin following a 200 mg loading dose alone and in combination with 1.25 mg/kg oral cyclosporin twice daily, the steady state plasma peak concentration (Cmax) of anidulafungin was not significantly altered by cyclosporin; however the steady state area under the concentration-time curve (AUC) was increased by 22%. An in vitro study has shown that anidulafungin has no effect on the metabolism of cyclosporin. Adverse events observed in this study were consistent with those observed in other studies where anidulafungin only was administered. No dosage adjustment of either drug is required when they are co-administered.
Voriconazole (CYP2C19, CYP2C9, CYP3A4 inhibitor and substrate): In a study of 17 healthy subjects who received 100 mg/day anidulafungin alone following a 200 mg loading dose, 200 mg twice daily oral voriconazole alone following 400 mg twice on the first day as loading doses, and both in combination, the steady state Cmax and AUC of anidulafungin and voriconazole were not significantly altered by co-administration. No dosage adjustment of either drug is required when co-administered.
Tacrolimus (CYP3A4 substrate): In a study of 35 healthy subjects who received a single oral dose of 5 mg tacrolimus alone, 100 mg/day anidulafungin alone following a 200 mg loading dose and both in combination, the steady state Cmax and AUC of anidulafungin and tacrolimus were not significantly altered by co-administration. No dosage adjustment of either drug is required when co-administered.
Liposomal amphotericin B: The pharmacokinetics of anidulafungin were examined in 27 patients (100 mg/day anidulafungin) who were co-administered with liposomal amphotericin B (doses up to 5 mg/kg/day). The population pharmacokinetic analysis showed that, the pharmacokinetics of anidulafungin were not significantly altered by co-administration with amphotericin B when compared to data from patients who did not receive amphotericin B. No dosage adjustment of anidulafungin is required.
Rifampicin (potent CYP450 inducer): The pharmacokinetics of anidulafungin were examined in 27 patients (50 or 75 mg/day anidulafungin) who were co-administered with rifampicin (doses up to 600 mg/day). The population pharmacokinetic analysis showed that when compared to data from patients that did not receive rifampicin, the pharmacokinetics of anidulafungin were not significantly altered by co-administration with rifampicin. No dosage adjustment of anidulafungin is required.
Caution For Usage
Special precautions for disposal and other handling: Anidulafungin must be reconstituted with sterile water for injection and subsequently diluted with ONLY 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion. The compatibility of reconstituted anidulafungin with intravenous substances, additives, or medications other than 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion has not been established.
Reconstitution of Water for Injection Presentation: Aseptically reconstitute each vial with 30 mL sterile water for injection to provide a concentration of 3.33 mg/mL. The reconstitution time can be up to 5 minutes.
The reconstituted solution may be stored at up to 25°C for 24 hours.
Dilution and Infusion of Water for Injection Presentation: Aseptically transfer the contents of the reconstituted vial(s) into an IV bag (or bottle) containing either 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion to obtain the appropriate anidulafungin concentration. The table as follows provides the volumes required for each dose. (See Table 3.)

Click on icon to see table/diagram/image

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If particulate matter or discoloration are identified, discard the solution.
The rate of infusion should not exceed 1.1 mg/minute (see Precautions and Adverse Reactions). The rate of infusion is equivalent to 1.4 mL/min for the 100 mg and 200 mg doses.
For single use only. Waste materials should be disposed of in accordance with local requirements.
Incompatibilities: This medicinal product must not be mixed or co-administered with other medicinal products or electrolytes except those mentioned previously.
Storage
Store medicinal product in a refrigerator (2°C-8°C). Excursions for 96 hours up to 25°C are permitted, and the powder can be returned to refrigerated storage.
For storage conditions of the reconstituted medicinal product, see Shelf-Life as follows.
Shelf-Life: 3 years.
Reconstituted Solution: The reconstituted solution may be stored at 25°C for up to 24 hours.
Chemical and physical in-use stability of the reconstituted solution has been demonstrated for 24 hours at 25°C.
From a microbiological point of view, following good aseptic practices, the reconstituted solution can be utilized for up to 24 hours when stored at 25°C.
Infusion Solution: The infusion solution may be stored at 25°C for 48 hours or stored frozen for at least 72 hours.
Chemical and physical in-use stability of the infusion solution has been demonstrated for 48 hours at 25°C.
From a microbiological point of view, following good aseptic practices, the infusion solution can be utilized for up to 48 hours from preparation when stored at 25°C.
MIMS Class
ATC Classification
J02AX06 - anidulafungin ; Belongs to the class of other systemic antimycotics.
Presentation/Packing
Powd for infusion (white to off-white lyophilized solid in vial) 100 mg x 1's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in